Prosecution Insights
Prosecution Insights
11 pending office actions • 8 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 1 (9%) |
| §112 only | 3 (27%) |
| Double-patenting only | 3 (27%) |
| Multi-statute (no §101) | 2 (18%) |
| No statute on record | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 33.1% | +39.0% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.5% |
| SHIM, DAVID M. | 1 | 57.8% | +55.9% |
| NATARAJAN, MEERA | 1 | 62.3% | +17.6% |
| HOWARD, ZACHARY C | 1 | 63.8% | +38.0% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 63.0% | +39.1% |
| TCHERKASSKAYA, OLGA V | 1 | 55.2% | +46.3% |
| JOHNSON, TIRONE DEREK | 1 | — | — |
| BELYAVSKYI, MICHAIL A | 1 | 64.1% | +27.7% |
| YAO, LEI | 1 | 59.8% | +65.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18739860 | PI4KIIIBETA INHIBITORS | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569648 | Pharmaceutical Compound | RZECZYCKI, PHILLIP MATTHEW | 53d |
| 18262938 | ORAL SOLID DOSE FORMULATIONS | TCHERKASSKAYA, OLGA V | — |
| 18258588 | INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN | JOHNSON, TIRONE DEREK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18613481 | METHODS OF TREATING AN IL-5 MEDIATED DISEASE BY ADMINISTERING AN IL-5 BINDING PROTEIN | HOWARD, ZACHARY C | 7d |
| 18569648 | Pharmaceutical Compound | RZECZYCKI, PHILLIP MATTHEW | 53d |
| 17950667 | CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN-3 AND METHODS FOR TREATING CANCER | YAO, LEI | 78d |
| 18728991 | GEPOTIDACIN AND VANCOMYCIN FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY STAPHYLOCOCCUS SAPROPHYTICUS | REYNOLDS, FRED H | — |
| 18739860 | PI4KIIIBETA INHIBITORS | WILLIS, DOUGLAS M | — |
| 18646178 | COMPOUNDS | SHIM, DAVID M. | — |
| 18697515 | Combination Therapies for Treating Cancer | NATARAJAN, MEERA | — |
| 18262938 | ORAL SOLID DOSE FORMULATIONS | TCHERKASSKAYA, OLGA V | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1643 | 1 |
| 1674 | 1 |
| 1625 | 1 |
| 1615 | 1 |
| 1675 | 1 |
| 1644 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18728991 | GEPOTIDACIN AND VANCOMYCIN FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY STAPHYLOCOCCUS SAPROPHYTICUS | REYNOLDS, FRED H | — | DP | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18739860 | PI4KIIIBETA INHIBITORS | WILLIS, DOUGLAS M | — | §112Other | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18646178 | COMPOUNDS | SHIM, DAVID M. | 1629 | §103Other | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18697515 | Combination Therapies for Treating Cancer | NATARAJAN, MEERA | 1643 | DP | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18613481 | METHODS OF TREATING AN IL-5 MEDIATED DISEASE BY ADMINISTERING AN IL-5 BINDING PROTEIN | HOWARD, ZACHARY C | 1674 | Other | Non-Final OA | 7d | Pending | Mar 22, 2024 |
| 18569648 | Pharmaceutical Compound | RZECZYCKI, PHILLIP MATTHEW | 1625 | §101§112 | Non-Final OA | 53d | Pending | Dec 13, 2023 |
| 18262938 | ORAL SOLID DOSE FORMULATIONS | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Final Rejection | — | Pending | Jul 26, 2023 |
| 18258588 | INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN | JOHNSON, TIRONE DEREK | 1675 | §102§103§112Other | Non-Final OA | — | Pending | Jun 21, 2023 |
| 18098792 | ANTIGEN BINDING PROTEINS | BELYAVSKYI, MICHAIL A | 1644 | DP | Final Rejection | — | Pending | Jan 19, 2023 |
| 17950667 | CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN-3 AND METHODS FOR TREATING CANCER | YAO, LEI | 1642 | §112 | Non-Final OA | 78d | Pending | Sep 22, 2022 |
| 17412070 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | SCHMITT, MICHAEL J | 1629 | §112Other | Final Rejection | 29d | Pending | Aug 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial